Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Payables (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Payables data on record, last reported at $2.1 million in Q3 2025.

  • For Q3 2025, Payables fell 17.02% year-over-year to $2.1 million; the TTM value through Sep 2025 reached $2.1 million, down 17.02%, while the annual FY2024 figure was $2.0 million, 18.73% down from the prior year.
  • Payables reached $2.1 million in Q3 2025 per MBRX's latest filing, down from $3.7 million in the prior quarter.
  • Across five years, Payables topped out at $4.1 million in Q2 2023 and bottomed at $1.4 million in Q4 2021.
  • Average Payables over 5 years is $2.4 million, with a median of $2.1 million recorded in 2025.
  • Peak YoY movement for Payables: soared 156.69% in 2022, then crashed 43.72% in 2023.
  • A 5-year view of Payables shows it stood at $1.4 million in 2021, then soared by 53.59% to $2.1 million in 2022, then rose by 19.24% to $2.5 million in 2023, then fell by 18.73% to $2.0 million in 2024, then increased by 4.24% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $2.1 million in Q3 2025, $3.7 million in Q2 2025, and $2.7 million in Q1 2025.